Efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery

Chad A. Knoderer, Elaine Cox, Michelle D. Berg, Andrea H. Webster, Mark Turrentine

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose. The efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery was evaluated. Methods. All patients age 18 years or younger who underwent cardiovascular surgery and received postoperative care from the cardiovascular surgery team between February and July 2006 (preintervention group) and between August 2006 and January 2007 (postintervention group) were eligible for study inclusion. Patients were excluded if they did not receive cefuroxime as postoperative prophylaxis, had a preexisting infection, underwent cardiac transplantation or extracorporeal membrane oxygenation, or underwent delayed sternal closure. The preintervention group received prolonged cefuroxime prophylaxis, and the postintervention group received 24 hours of cefuroxime prophylaxis. Data collected included patient demographics and clinical and laboratory markers of infection, as well as microbiological evidence of and treatment courses for documented or presumed infections. Results. A total of 210 patients were enrolled in the study. The number of patients who required additional antibiotics for suspicion of clinical infection did not significantly differ between the preintervention and postintervention groups (18.6% versus 26.9%, respectively), nor did the rate of documented infection (bacteremia, urinary tract infection, endocarditis, sepsis) (42.1% versus 48.3%, respectively). Moreover, indications for the antibiotics initiated were similar between the preintervention and postintervention groups. Clinical and laboratory signs of postoperative infection were similar between groups. There were no differences in postoperative white blood cell counts, peak serum glucose levels, and platelet nadir between groups. Conclusion. Limiting postoperative cefuroxime prophylaxis to 24 hours did not increase infectious outcomes in pediatric patients.

Original languageEnglish
Pages (from-to)909-914
Number of pages6
JournalAmerican Journal of Health-System Pharmacy
Volume68
Issue number10
DOIs
StatePublished - May 15 2011

Fingerprint

Cefuroxime
Pediatrics
Infection
Biomarkers
Laboratory Infection
Anti-Bacterial Agents
Extracorporeal Membrane Oxygenation
Postoperative Care
Heart Transplantation
Bacteremia
Endocarditis
Leukocyte Count
Urinary Tract Infections
Sepsis
Blood Platelets
Demography
Glucose
Serum

Keywords

  • Bacterial infections
  • Cardiovascular surgical procedures
  • Cefuroxime
  • Cephalosporins
  • Pediatrics
  • Postoperative complications

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery. / Knoderer, Chad A.; Cox, Elaine; Berg, Michelle D.; Webster, Andrea H.; Turrentine, Mark.

In: American Journal of Health-System Pharmacy, Vol. 68, No. 10, 15.05.2011, p. 909-914.

Research output: Contribution to journalArticle

@article{e1c527842e124f7cb1fbbdb8af8d7c18,
title = "Efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery",
abstract = "Purpose. The efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery was evaluated. Methods. All patients age 18 years or younger who underwent cardiovascular surgery and received postoperative care from the cardiovascular surgery team between February and July 2006 (preintervention group) and between August 2006 and January 2007 (postintervention group) were eligible for study inclusion. Patients were excluded if they did not receive cefuroxime as postoperative prophylaxis, had a preexisting infection, underwent cardiac transplantation or extracorporeal membrane oxygenation, or underwent delayed sternal closure. The preintervention group received prolonged cefuroxime prophylaxis, and the postintervention group received 24 hours of cefuroxime prophylaxis. Data collected included patient demographics and clinical and laboratory markers of infection, as well as microbiological evidence of and treatment courses for documented or presumed infections. Results. A total of 210 patients were enrolled in the study. The number of patients who required additional antibiotics for suspicion of clinical infection did not significantly differ between the preintervention and postintervention groups (18.6{\%} versus 26.9{\%}, respectively), nor did the rate of documented infection (bacteremia, urinary tract infection, endocarditis, sepsis) (42.1{\%} versus 48.3{\%}, respectively). Moreover, indications for the antibiotics initiated were similar between the preintervention and postintervention groups. Clinical and laboratory signs of postoperative infection were similar between groups. There were no differences in postoperative white blood cell counts, peak serum glucose levels, and platelet nadir between groups. Conclusion. Limiting postoperative cefuroxime prophylaxis to 24 hours did not increase infectious outcomes in pediatric patients.",
keywords = "Bacterial infections, Cardiovascular surgical procedures, Cefuroxime, Cephalosporins, Pediatrics, Postoperative complications",
author = "Knoderer, {Chad A.} and Elaine Cox and Berg, {Michelle D.} and Webster, {Andrea H.} and Mark Turrentine",
year = "2011",
month = "5",
day = "15",
doi = "10.2146/ajhp100563",
language = "English",
volume = "68",
pages = "909--914",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "10",

}

TY - JOUR

T1 - Efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery

AU - Knoderer, Chad A.

AU - Cox, Elaine

AU - Berg, Michelle D.

AU - Webster, Andrea H.

AU - Turrentine, Mark

PY - 2011/5/15

Y1 - 2011/5/15

N2 - Purpose. The efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery was evaluated. Methods. All patients age 18 years or younger who underwent cardiovascular surgery and received postoperative care from the cardiovascular surgery team between February and July 2006 (preintervention group) and between August 2006 and January 2007 (postintervention group) were eligible for study inclusion. Patients were excluded if they did not receive cefuroxime as postoperative prophylaxis, had a preexisting infection, underwent cardiac transplantation or extracorporeal membrane oxygenation, or underwent delayed sternal closure. The preintervention group received prolonged cefuroxime prophylaxis, and the postintervention group received 24 hours of cefuroxime prophylaxis. Data collected included patient demographics and clinical and laboratory markers of infection, as well as microbiological evidence of and treatment courses for documented or presumed infections. Results. A total of 210 patients were enrolled in the study. The number of patients who required additional antibiotics for suspicion of clinical infection did not significantly differ between the preintervention and postintervention groups (18.6% versus 26.9%, respectively), nor did the rate of documented infection (bacteremia, urinary tract infection, endocarditis, sepsis) (42.1% versus 48.3%, respectively). Moreover, indications for the antibiotics initiated were similar between the preintervention and postintervention groups. Clinical and laboratory signs of postoperative infection were similar between groups. There were no differences in postoperative white blood cell counts, peak serum glucose levels, and platelet nadir between groups. Conclusion. Limiting postoperative cefuroxime prophylaxis to 24 hours did not increase infectious outcomes in pediatric patients.

AB - Purpose. The efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery was evaluated. Methods. All patients age 18 years or younger who underwent cardiovascular surgery and received postoperative care from the cardiovascular surgery team between February and July 2006 (preintervention group) and between August 2006 and January 2007 (postintervention group) were eligible for study inclusion. Patients were excluded if they did not receive cefuroxime as postoperative prophylaxis, had a preexisting infection, underwent cardiac transplantation or extracorporeal membrane oxygenation, or underwent delayed sternal closure. The preintervention group received prolonged cefuroxime prophylaxis, and the postintervention group received 24 hours of cefuroxime prophylaxis. Data collected included patient demographics and clinical and laboratory markers of infection, as well as microbiological evidence of and treatment courses for documented or presumed infections. Results. A total of 210 patients were enrolled in the study. The number of patients who required additional antibiotics for suspicion of clinical infection did not significantly differ between the preintervention and postintervention groups (18.6% versus 26.9%, respectively), nor did the rate of documented infection (bacteremia, urinary tract infection, endocarditis, sepsis) (42.1% versus 48.3%, respectively). Moreover, indications for the antibiotics initiated were similar between the preintervention and postintervention groups. Clinical and laboratory signs of postoperative infection were similar between groups. There were no differences in postoperative white blood cell counts, peak serum glucose levels, and platelet nadir between groups. Conclusion. Limiting postoperative cefuroxime prophylaxis to 24 hours did not increase infectious outcomes in pediatric patients.

KW - Bacterial infections

KW - Cardiovascular surgical procedures

KW - Cefuroxime

KW - Cephalosporins

KW - Pediatrics

KW - Postoperative complications

UR - http://www.scopus.com/inward/record.url?scp=79957640680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957640680&partnerID=8YFLogxK

U2 - 10.2146/ajhp100563

DO - 10.2146/ajhp100563

M3 - Article

C2 - 21546642

AN - SCOPUS:79957640680

VL - 68

SP - 909

EP - 914

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 10

ER -